Breast Cancer Trial, Recruiting NCT06454864 Sponsor: University of Toronto Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT06454864
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are biologically female
  • People who have been diagnosed with stage I, II, or III breast cancer
  • People who were post-menopausal at the time of their breast cancer diagnosis, meaning their last menstrual period was at least 12 months before diagnosis
  • People who have taken a type of hormone-blocking medication called aromatase inhibitors for 12 months or more in the past (not necessarily currently)
  • People with a body mass index (BMI) of 25 or higher (confirm with trial site if unsure of your BMI)
  • People who are willing and able to complete all study activities
  • People who are able to travel to the University once per week for 24 weeks

Who may not be able to join:

  • People who have received chemotherapy in the past 11 months
  • People who have been diagnosed with cancer that has spread to other parts of the body (metastatic cancer), including if this happened after an early-stage breast cancer diagnosis
  • People who are currently taking a hormone-blocking medication called tamoxifen
  • People who are currently receiving chemotherapy, targeted cancer therapy, or radiation treatment
  • People who have been diagnosed with heart disease, type 2 diabetes, non-alcoholic fatty liver disease, an uncontrolled thyroid condition, or a breathing condition such as severe asthma or COPD
  • People who have significant symptoms that may suggest heart, diabetes, or kidney problems — such as chest pain, shortness of breath at rest or with light activity, dizziness or fainting, swollen ankles, irregular heartbeat, unusual leg pain when walking, a known heart murmur, or unusual tiredness with everyday activities
  • People with certain serious heart or cardiovascular conditions that make supervised maximum-effort exercise testing unsafe, such as a recent heart attack, heart failure, blood clots in the lungs, heart inflammation, uncontrolled irregular heartbeat, stroke, very high blood pressure (above 200/100 mmHg), or a cancer diagnosis other than skin cancer (confirm with trial site for full list)
  • People who are unable to give informed consent or communicate in English
  • People who are currently pregnant or breastfeeding, or have been in the past 3 months
  • People who have mobility limitations that affect their ability to do aerobic exercise, such as using a wheelchair, walker, or having a limp that affects walking
  • People who have smoked cigarettes or marijuana in the past 3 months
  • People who are currently taking or have taken hormone medications of any kind in the past 3 months
  • People who cannot have a research MRI scan, for example due to a pacemaker or certain metal implants
  • People with a BMI over 40
  • People with severe claustrophobia (fear of enclosed spaces)
  • People who are already doing more than 30 minutes per week of moderate-to-vigorous aerobic exercise
  • People who have been following a diet that heavily restricts entire food groups or eating times in the past 3 months (such as vegan, ketogenic, carnivore, or one-meal-a-day diets)
  • People who have lost more than 5 kg in weight in the past 3 months
  • People who are currently taking weight loss medications
  • People who have a diagnosed eating disorder, or who suspect they may have an undiagnosed eating disorder
  • People who plan to be unavailable for more than 4 weeks total across the 6-month program, or more than 2 weeks during the first 12 weeks
  • People who have an allergy to local anaesthetics

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Amy A Kirkham, PhD, University of Toronto

Phone: 416-946-4069

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Toronto
Registry
ClinicalTrials.gov
Start date
1 July 2024
Est. completion
1 October 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Insulin resistance

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov